Ventyx Biosciences, Inc. Cash Flow Statement
VTYX / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Ventyx Biosciences, Inc. used $131M in operating cash flow and negative free cash flow of $131M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$135.1M | -$193.0M | -$108.4M | -$83.7M | -$28.2M |
| Depreciation & Amortization | $266.0K | $158.0K | $123.0K | $30.0K | - |
| Operating Cash Flow | -$130.9M | -$166.5M | -$98.8M | -$38.6M | -$6.2M |
| Capital Expenditures | $241.0K | $514.0K | $275.0K | $262.0K | - |
| Free Cash Flow | -$131.1M | -$167.0M | -$99.0M | -$38.9M | - |